Study of immuno-Cell therapy for advanced and recurrent gastrointestinal and Hepato-biliary-pancreatic carcinoma

Study of immuno-Cell therapy for advanced and recurrent gastrointestinal and Hepato-biliary-pancreatic carcinoma - Study of immuno-Cell therapy for advanced and recurrent gastrointestinal carcinoma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013187

Enrollment

Registered

2014-03-11

Start date

2014-04-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced and recurrent gastrointestinal and hepato-biliary-pancreatic carcinoma

Interventions

Immunocell therapy using activated lymphocytes injections

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Advanced and recurrent gastrointestinal and hepato-billirary pancreatic carcinoma 2.Age over 20 years 3.Performance status 0-2 4.Adequate organ function WBC:over 2,000/ mm3 Plt:over 50,000/mm3 Hb:over 8.5 g/dl Cr:under 2.0mg/dl 5.Written informed consent

Exclusion criteria

Exclusion criteria: 1.patient who was malignant lymphoma, or leukemia 2.HTLV-1 antibody, or HIV antibody is positive 3.patient who has interstitial pneumonia 4.patient who has activated autoimmune 5.patient who has activated cardiac disease 6.patient who has severe drug allergy 7.pregnant

Design outcomes

Primary

Measure	Time frame
Efficacy and responsibility	—

Countries

Japan

Contacts

Public ContactHideaki Shimada

Toho University School of Medicine Department of Surgery

hideaki.shimada@med.toho-u.ac.jp03-3762-4151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026